- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01624688
Optimizing Tattoo Removal: a Side-by-side Comparison in the Search for One Treatment Tattoo Removal
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Efficient tattoo removal is of special concern to dermatology, where tattoo removal is a common request. Current tattoo removal techniques using once monthly treatment with quality-switched (QS) lasers are relatively effective, but not efficient. Numerous treatments are required and complete removal of ink is usually rare, making the process time-consuming, expensive and, sometimes, disappointing. The broad objective of this study is to combine effective methods for tattoo removal based on current knowledge to establish a protocol which significantly improves laser tattoo removal, aiming to selectively remove most tattoos in one office visit.
The proposed study is a prospective, side-by-side comparison of four tattoo treatment protocols using a combination of ablative fractional and q-switched (QS) laser techniques. 32 subjects with tattoos recruited from the community will receive all four treatments, one on each randomly-assigned, equal quadrant of the same tattoo. The different treatment protocols are as follows: 1. one round of QS laser treatment, which is the current treatment standard 2. four repeat treatments with the QS laser with a 20 minute delay in between 3. four repeat treatments at 20 minute intervals with the QS laser combined with an ablative fractional laser treatment 4. four repeat treatments at 20 minute intervals with the QS laser plus treatment with the ablative fractional laser, in combination with topical urea application. Following this initial round of treatments, the subject will have the option to choose his or her preferred treatment protocol which will then be used to treat the entire tattoo again one month later. Previous studies indicate that the majority of tattoos will be completely or nearly completely removed in this study, providing a potential benefit to those who enroll in the study. The primary measures of efficacy are (a) blinded evaluation of improvement from standard digital photographs taken before and after the treatments, including number of tattoos that are completely gone, and (b) digital analysis of tattoo removal from those photos. Other study endpoints include patient's preferred removal technique, evaluation of tattoo ink on dressings, inflammatory and pigmentary alterations and changes in skin texture.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Wellman Center for Photomedicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects between the ages of 18 and 50 years old, male or female.
- Subjects with tattoos that are between 16 and 400 cm2, both amateur and professional
- Willingness to participate in the study
- Willingness to shield tattoo completely from sun exposure
- Willingness to receive EXPERIMENTAL treatment
- Informed consent agreement signed by the subject
- Willingness to follow the treatment schedule and post treatment care requirements
Exclusion Criteria:
- Subjects with recent sun exposure and suntan in the area to be treated
- Allergic tattoos (hypersensitivity to tattoo ink)
- History of vitiligo
- Tattoos located on the neck or face
- Subjects unwilling to tolerate partial removal of the tattoo in this study
- Infection or skin disease in the area to be treated
- Subjects who are immunosuppressed
- Subject is unable to comply with treatment, home care or follow-up visits
- Subject is pregnant or nursing
- Allergy to lidocaine
- Liver failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tattoo Clearance
Time Frame: 2 months after treatment
|
2 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient's preferred removal technique
Time Frame: 2 months after treatment
|
2 months after treatment
|
|
Post treatment skin changes
Time Frame: 2 months after treatment
|
inflammatory and pigmentary alterations and changes in skin texture after treatment
|
2 months after treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2011P001091
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tattoo Removal
-
Cutera Inc.CompletedTattoo RemovalUnited States
-
Cutera Inc.Completed
-
Cutera Inc.CompletedTattoo RemovalUnited States
-
Cutera Inc.WithdrawnLaser Tattoo RemovalCanada
-
Cutera Inc.Completed
-
Cutera Inc.Completed
-
Cutera Inc.CompletedTattoo RemovalUnited States
-
Assaf-Harofeh Medical CenterUnknownRemoval of Colors Tattoo (Multiple Colors)Israel
Clinical Trials on Tattoo Removal
-
Cupola Medical LtdTerminated
-
University Hospital, Strasbourg, FranceCompletedBreast Cancer | Right or Left Breast Mammary Reconstruction | Malignant Neoplasm Reconstruction by Tattoo of Areola of Female BreastFrance
-
Henry Ford Health SystemEphemeral Solutions Inc.Active, not recruitingCancer, Treatment-Related | Tattoo; PigmentationUnited States
-
Yale UniversityCompletedAndrogenic AlopeciaUnited States
-
Dana-Farber Cancer InstituteTerminated
-
Gaziosmanpasa Research and Education HospitalRecruiting
-
King Hussein Cancer CenterCompleted
-
Yale UniversityCompletedAlopecia AreataUnited States
-
Charite University, Berlin, GermanyUniversity Medicine Greifswald; Rheinisch-Westfälische Technische Hochschule...Unknown
-
IRCCS San RaffaeleCompletedPancreatic Fistula | Complication,Postoperative | PROMs | Pancreas DiseaseItaly